HardwareWageningen, NetherlandsFounded 2021· One of 1740 Hardware companies tracked by AMPulse
Develops the CHIMERA 5-in-1 biofabrication platform for 4D bioprinting of human tissues with embedded biosensors and bioelectronics, enabling high-throughput production for regenerative medicine and drug testing.
CEO / Founder
John Zandbergen
Team Size
11-50
Stage
Active
Total Funding
$455.22M
Latest Round
Grant
Key Investors
National Growth Fund (NxtGen HighTech); ION+2 fund (EU REACT-EU program)
Technology & Products
Key Products
CHIMERA biofabrication platform; Human biomaterials (e.g., HumaDerm Human Skin Collagen); Cyborganic human tissue models with embedded biosensors
Technological Advantage
Proprietary patent-pending electric field methodology enables precise deposition of cells and biomaterials for complex tissue formation, offering a multi-technology solution that accelerates tissue production and integrates biosensors.
Differentiation
Value Proposition
Reduces reliance on animal testing by providing biofabricated human tissue models with real-time physiological monitoring, accelerating drug discovery and regenerative medicine development.
How They Differentiate
CHIMERA platform combines five biofabrication technologies in one system vs. competitors' single-technology focus, enabling multi-complex tissue production with embedded biosensors for real-time monitoring.
Market & Competition
Target Customers
Pharmaceutical, cosmetic, chemical, and MedTech companies; academic and research institutions
Industry Verticals
Pharmaceuticals; Cosmetics; Medical Devices; Biotechnology; Research and Academia
Secured over €1 million in prior funding; raising €4.5 million Seed round with €1 million soft commitment; developing CHIMERA platform for high-throughput production
Major Milestones
Founded in March 2021; Launched CHIMERA biofabrication platform in 2024; Secured participation in €450 million NxtGen HighTech initiative; Entered distribution partnership with Humabiologics for European market
Ourobionics develops the CHIMERA 5-in-1 biofabrication platform, a modular system that combines 3D Bio-ElectroSpraying, Cell-ElectroSpinning, Bio-ElectroJetting, Melt/Cell ElectroWriting, and extrusion bioprinting into one machine. This multi-technology approach enables 4D bioprinting of human tissues with embedded biosensors and bioelectronics, allowing real-time physiological monitoring. The company's proprietary electric field methodology aims to improve precision in depositing cells and biomaterials for complex tissue formation.
The platform targets pharmaceutical, cosmetic, and MedTech companies, as well as academic and research institutions, offering an alternative to animal testing for drug discovery and regenerative medicine. Ourobionics also supplies human biomaterials such as HumaDerm Human Skin Collagen and Cyborganic tissue models with integrated sensors. A distribution partnership with Humabiologics covers the European market, and the company participates in the Smart Biomaterials Consortium.
Founded in 2021 and based in Wageningen, Netherlands, Ourobionics has secured over €1 million in prior funding and is raising a €4.5 million Seed round with a €1 million soft commitment. It is also part of the €450 million NxtGen HighTech initiative. Competitors include Organovo, CELLINK (BICO Group), and Aspect Biosystems, which typically focus on single-technology bioprinting systems. Ourobionics differentiates by combining five technologies in one platform with embedded bioelectronics, though the technology remains in early commercial stages.